CAMBRIDGE, Mass., April 17, 2017 /PRNewswire/ -- Merrimack
Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that
Daryl Drummond, Ph.D. has been
appointed Head of Research. Dr. Drummond, an expert and pioneer in
the field of nanotherapeutics, has held various leadership roles at
Merrimack, including most recently as Vice President of Discovery
and Team Leader for Merrimack's early-stage pipeline. Dr. Drummond
was also integral in the invention and development of ONIVYDE®,
which was recently sold to Ipsen S.A. for up to $1.025 billion.
"Daryl's successful track record of advancing programs from the
discovery stage into meaningful therapeutics is exactly the kind of
leadership that our research organization needs to move our drug
candidates forward and achieve our objective to help cancer
patients," said Richard Peters,
M.D., Ph.D., President and Chief Executive Officer. "He will
oversee a team of scientists who will continue to generate critical
data for the promising candidates in our clinical and preclinical
pipeline, consisting of engineered antibodies and antibody-directed
nanotherapeutics."
Prior to joining Merrimack, Dr. Drummond was Director of
Liposome Research and Development at Hermes BioSciences, a biotech
company that was acquired by Merrimack in 2009. Prior to
that, he completed his post-doctorate in the laboratory of
Demetrios Papahadjopoulos at
California Pacific Medical Center in San Francisco. Dr.
Drummond received a Ph.D. in Biochemistry from Indiana University, with an emphasis on membrane
biochemistry and biophysics, and completed an Executive Training
Program in Leadership and Strategy in Pharmaceuticals and Biotech
from Harvard Business School.
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking
cancer to ensure that patients and their families live fulfilling
lives. Our mission is to transform cancer care through the smart
design and development of targeted solutions based on the deep
understanding of cancer pathways and biological markers. All our
product candidates, including three in clinical studies and several
others in preclinical development, fit into our strategy of 1)
understanding the biological problems we are trying to solve, 2)
designing specific solutions and 3) developing those solutions for
biomarker-selected patients. This three-pronged strategy seeks to
ensure optimal patient outcomes. For more information, please visit
Merrimack's website at www.merrimack.com.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Merrimack constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. Actual results may differ
materially from those indicated by such forward-looking statements.
Merrimack anticipates that subsequent events and developments will
cause its views to change. However, while Merrimack may elect to
update these forward-looking statements at some point in the
future, Merrimack specifically disclaims any obligation to do
so.
Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/merrimack-appoints-daryl-drummond-phd-as-head-of-research-300440001.html
SOURCE Merrimack Pharmaceuticals, Inc.